pbf-509
Small moleculeexperimental
Clinical trial activity
3 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2012 (NCT01691924)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Adenosine A2a receptorANTAGONIST
ADORA2A antagonist
Chemistry & pharmacology
Loading structure…
SMILES
Nc1nc(-n2cccn2)nc(-n2cccn2)c1Br- Mol. weight
- 306.13 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3694769 ↗
- ChEMBLCHEMBL3545009 ↗
Also known as
- pbf-509
- pbf-509
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02403193 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2015 | Novartis, Paloma Pharmaceuticals, Inc., University of South Florida |
| NCT02111330 | Phase 1 | Mar 1, 2014 | CIM Sant Pau, Palo Biofarma, S.L, University of Barcelona |
| NCT01691924 | Phase 1 | Oct 1, 2012 | Palo Biofarma, S.L, University of Barcelona |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Palo Biofarma, S.L | For profit | 2 | 0 | 1 | 2012 |
| University of Barcelona | Academic/Hospital | 2 | 2 | 1 | 2012 |
| CIM Sant Pau | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Novartis | For profit | 1 | 0 | 1 | 2015 |
| Paloma Pharmaceuticals, Inc. | For profit | 1 | 1 | 1 | 2015 |
| University of South Florida | Academic/Hospital | 1 | 0 | 1 | 2015 |
6 organizations
Page 1 / 1